| |
| |
|
| Insider
Information: |
Moriarty John B |
| Relationship: |
|
| City: |
Cheshire |
| State: |
CT |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
74,537 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$13,603,003 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
74,537 |
|
|
| Total
Value |
$13,603,003 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alexion Pharmaceuticals Inc |
ALXN |
EVP & General Counsel |
2018-02-08 |
74,537 |
2012-12-10 |
0 |
Premium* |
|
|
Portola Pharmaceuticals Inc |
PTLA |
EVP, General Counsel |
2020-07-02 |
0 |
2018-03-29 |
0 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
|
2024-01-23 |
0 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MRTX |
Mirati Therapeutics, Inc. |
Chief Legal Officer |
• • – |
2024-01-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(72,335) |
0 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
Chief Legal Officer |
• – – |
2023-08-09 |
4 |
A |
$37.00 |
$824,989 |
D/D |
22,297 |
71,660 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
Chief Legal OfficerOfficer |
• – – |
2023-06-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
49,363 |
|
% |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, General Counsel |
• – – |
2020-07-02 |
4 |
D |
$18.00 |
$232,074 |
D/D |
(12,893) |
0 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, General Counsel |
• – – |
2020-03-02 |
4 |
D |
$9.68 |
$41,885 |
D/D |
(4,327) |
49,976 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, General Counsel |
• – – |
2020-02-03 |
4 |
D |
$12.89 |
$45,682 |
D/D |
(3,544) |
53,184 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, General Counsel |
• – – |
2020-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
16,250 |
56,728 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, General Counsel |
• – – |
2019-03-04 |
4 |
D |
$33.42 |
$143,606 |
D/D |
(4,297) |
39,952 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, General Counsel |
• – – |
2019-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
18,750 |
43,750 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, General Counsel |
• – – |
2018-03-29 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
• – – |
2018-02-08 |
4 |
S |
$115.70 |
$389,099 |
D/D |
(3,363) |
74,537 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
• – – |
2018-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
27,989 |
77,900 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
• – – |
2018-02-05 |
4 |
S |
$117.26 |
$147,865 |
D/D |
(1,261) |
49,911 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
• – – |
2017-03-01 |
4 |
S |
$132.50 |
$37,365 |
D/D |
(282) |
44,672 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
• – – |
2017-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,500 |
51,172 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
• – – |
2017-02-28 |
4 |
S |
$131.71 |
$119,856 |
D/D |
(910) |
44,954 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
• – – |
2017-02-27 |
4 |
S |
$131.20 |
$80,294 |
D/D |
(612) |
45,864 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
• – – |
2017-02-09 |
4 |
S |
$126.84 |
$21,182 |
D/D |
(167) |
46,476 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
• – – |
2016-12-12 |
4 |
S |
$118.61 |
$123,829 |
D/D |
(1,044) |
50,181 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
• – – |
2016-08-08 |
4 |
S |
$137.14 |
$18,514 |
D/D |
(135) |
51,225 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
• – – |
2016-06-13 |
4 |
S |
$135.72 |
$124,591 |
D/D |
(918) |
51,360 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
• – – |
2016-02-29 |
4 |
S |
$138.91 |
$166,833 |
D/D |
(1,201) |
52,278 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
• – – |
2016-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
53,479 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
• – – |
2016-02-08 |
4 |
S |
$138.02 |
$363,577 |
D/D |
(2,633) |
48,501 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & General Counsel |
• – – |
2016-02-05 |
4 |
S |
$141.75 |
$282,447 |
D/D |
(1,969) |
51,134 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
